Verena Lentsch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Verena Lentsch has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
- Emma Slack
Department of Health Sciences and Technology, Swiss Federal Institute of Technology, Zurich, Switzerland
9 shared publications Selma Aslani
Institute for Food, Nutrition and Health, ETH Zurich, Zurich, Switzerland
6 shared publications- Médéric Diard
Biozentrum, University of Basel, Basel, Switzerland
5 shared publications - Claudia Moresi
Institute for Food, Nutrition and Health, ETH Zurich, Zurich, Switzerland
4 shared publications - Wolf-Dietrich Hardt
Institute of Microbiology, Department of Biology, ETH Zurich, Zurich, Switzerland
4 shared publications - Claude Loverdo
Sorbonne Universite
3 shared publications
Latest Publications
- Open Access
- 24 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Phage-steering permits antibody-mediated clearance of E. coli K1 from the gut
Escherichia coli (E. coli) strains expressing the capsule serotype K1 (E. coli K1) are a prevalent cause of neonatal sepsis and meningitis. The gut microbiota of healthy adults is a natural reservoir of E. coli K1, from which it can spread to extra-intestinal sites or be transmitted from mother to infant during birth. Accordingly, shifting gut colonization from potentially pathogenic E. coli strains to more benign strains could reduce the risk of disease. Here, we leverage selective pressures exerted by bacteriophage and mucosal antibodies to limit gut colonization by E. coli K1 and prevent its transmission. K1-specific bacteriophages (phages) rapidly drive a within-host evolution of capsule-less mutants with exposed surface O-antigens. These mutants become susceptible to vaccine-induced intestinal IgA targeting the bacterial O-antigen, allowing competitive exclusion by the probiotic strain E. coli Nissle. In a murine vertical transmission model, 77% of pups were protected from transmission of E. coli K1 when the mother was vaccinated and treated with phages, whereas E. coli K1 was detected in most pups by day 10 of life when the mother received vaccination or phage therapy alone. Although the high diversity of E. coli makes generalization challenging, combining vaccination with phage-steering represents a promising approach for further exploration in eliminating infectious reservoirs.
- 24 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessPhage-steering permits antibody-mediated clearance of E. coli K1 from the gut
Escherichia coli (E. coli) strains expressing the capsule serotype K1 (E. coli K1) are a prevalent cause of neonatal sepsis and meningitis. The gut microbiota of healthy adults is a natural reservoir of E. coli K1, from which it can spread to extra-intestinal sites or be transmitted from mother to infant during birth. Accordingly, shifting gut colonization from potentially pathogenic E. coli strains to more benign strains could reduce the risk of disease. Here, we leverage selective pressures exerted by bacteriophage and mucosal antibodies to limit gut colonization by E. coli K1 and prevent its transmission. K1-specific bacteriophages (phages) rapidly drive a within-host evolution of capsule-less mutants with exposed surface O-antigens. These mutants become susceptible to vaccine-induced intestinal IgA targeting the bacterial O-antigen, allowing competitive exclusion by the probiotic strain E. coli Nissle. In a murine vertical transmission model, 77% of pups were protected from transmission of E. coli K1 when the mother was vaccinated and treated with phages, whereas E. coli K1 was detected in most pups by day 10 of life when the mother received vaccination or phage therapy alone. Although the high diversity of E. coli makes generalization challenging, combining vaccination with phage-steering represents a promising approach for further exploration in eliminating infectious reservoirs.
- Open Access
- 25 November 2025
- Published by Springer Nature in Nature
- Vol. 648 (8093) , E7
Author Correction: Spatial fibroblast niches define Crohn’s fistulae
- 25 November 2025
- Published by Springer Nature in Nature
- Vol. 648 (8093) , E7
Open AccessAuthor Correction: Spatial fibroblast niches define Crohn’s fistulae
- Open Access
- 12 November 2025
- Published by Springer Nature in Nature
- Vol. 649 (8097) , 703-712
Spatial fibroblast niches define Crohn’s fistulae
Crohn’s disease often presents with fistulae, abnormal tunnels that connect the intestine to the skin or other organs. Despite their profound effect on morbidity, the molecular basis of fistula formation remains unclear, largely owing to the challenge of capturing intact fistula tracts and their inherent heterogeneity 1–3 . Here we construct a subcellular-resolution spatial atlas of 68 intestinal fistulae spanning diverse anatomical locations. We describe fistula-associated epithelial, immune and stromal cell states, revealing abnormal zonation of growth factors and morphogens linked to establishment of tunnelling anatomy. We identify fistula-associated stromal (FAS) fibroblasts, which are assembled in concentric layers: a proliferative, lumen-adjacent zone beneath neutrophil and macrophage-rich granulation tissue, an active lesion core of FAS cells and a quiescent, pro-fibrotic outer zone. We examine the architecture of the extracellular matrix in the fistula tract and demonstrate that FAS populations associate with distinct collagen structures, exhibiting properties ranging from proliferation, migration and extracellular matrix remodelling to dense collagen deposition and fibrosis. We define niches supporting epithelialization of fistula tunnels and a FAS-like population that is detected at the base of ulcers in non-penetrating Crohn’s disease. Our study demonstrates that common molecular pathways and cellular niches underpin fistulae across intestinal locations, revealing the cellular protagonists of fistula establishment and persistence. This resource will inform the development of model systems and interventions to mitigate aberrant fibroblast activity while preserving their regenerative properties in Crohn’s disease.
- 12 November 2025
- Published by Springer Nature in Nature
- Vol. 649 (8097) , 703-712
Open AccessSpatial fibroblast niches define Crohn’s fistulae
Crohn’s disease often presents with fistulae, abnormal tunnels that connect the intestine to the skin or other organs. Despite their profound effect on morbidity, the molecular basis of fistula formation remains unclear, largely owing to the challenge of capturing intact fistula tracts and their inherent heterogeneity 1–3 . Here we construct a subcellular-resolution spatial atlas of 68 intestinal fistulae spanning diverse anatomical locations. We describe fistula-associated epithelial, immune and stromal cell states, revealing abnormal zonation of growth factors and morphogens linked to establishment of tunnelling anatomy. We identify fistula-associated stromal (FAS) fibroblasts, which are assembled in concentric layers: a proliferative, lumen-adjacent zone beneath neutrophil and macrophage-rich granulation tissue, an active lesion core of FAS cells and a quiescent, pro-fibrotic outer zone. We examine the architecture of the extracellular matrix in the fistula tract and demonstrate that FAS populations associate with distinct collagen structures, exhibiting properties ranging from proliferation, migration and extracellular matrix remodelling to dense collagen deposition and fibrosis. We define niches supporting epithelialization of fistula tunnels and a FAS-like population that is detected at the base of ulcers in non-penetrating Crohn’s disease. Our study demonstrates that common molecular pathways and cellular niches underpin fistulae across intestinal locations, revealing the cellular protagonists of fistula establishment and persistence. This resource will inform the development of model systems and interventions to mitigate aberrant fibroblast activity while preserving their regenerative properties in Crohn’s disease.
- 4 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 388 (6742) , 74-81
Vaccine-enhanced competition permits rational bacterial strain replacement in the gut
Colonization of the intestinal lumen precedes invasive infection for a wide range of enteropathogenic and opportunistic pathogenic bacteria. We show that combining oral vaccination with engineered or selected niche-competitor strains permits pathogen exclusion and strain replacement in the mouse gut lumen. This approach can be applied either prophylactically to prevent invasion of nontyphoidal Salmonella strains, or therapeutically to displace an established Escherichia coli. Both intact adaptive immunity and metabolic niche competition are necessary for efficient vaccine-enhanced competition. Our findings imply that mucosal antibodies have evolved to work in the context of gut microbial ecology by influencing the outcome of competition. This has broad implications for the elimination of pathogenic and antibiotic-resistant bacterial reservoirs and for rational microbiota engineering.
- 4 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 388 (6742) , 74-81
Vaccine-enhanced competition permits rational bacterial strain replacement in the gut
Colonization of the intestinal lumen precedes invasive infection for a wide range of enteropathogenic and opportunistic pathogenic bacteria. We show that combining oral vaccination with engineered or selected niche-competitor strains permits pathogen exclusion and strain replacement in the mouse gut lumen. This approach can be applied either prophylactically to prevent invasion of nontyphoidal Salmonella strains, or therapeutically to displace an established Escherichia coli. Both intact adaptive immunity and metabolic niche competition are necessary for efficient vaccine-enhanced competition. Our findings imply that mucosal antibodies have evolved to work in the context of gut microbial ecology by influencing the outcome of competition. This has broad implications for the elimination of pathogenic and antibiotic-resistant bacterial reservoirs and for rational microbiota engineering.
- Open Access
Surface crosslinking of virus-like particles increases resistance to proteases, low pH, and mechanical stress for mucosal applications
Virus-like particles (VLPs) are emerging as nano-scaffolds in a variety of biomedical applications including the delivery of vaccine antigens and therapeutic molecules. These soft, colloidal, and proteinaceous structures are nevertheless susceptible to environmental factors such as mechanical stress, proteases and low pH which limit their usefulness, particularly for mucosal applications. We addressed this issue by crosslinking multiple surface sites using polyethylene glycol linkers. Surface crosslinking enhanced the colloidal stability and mechanical strength of VLPs against pH, proteases, and mechanical stresses. Chemical crosslinking thus offers a viable means to enhance resilience of VLPs in mucosal applications. Teaser Polyethylene glycol crosslinking virus-like particle (VLP) capsids enhanced the stability and strength of VLPs in mucosal environments.
Open AccessSurface crosslinking of virus-like particles increases resistance to proteases, low pH, and mechanical stress for mucosal applications
Virus-like particles (VLPs) are emerging as nano-scaffolds in a variety of biomedical applications including the delivery of vaccine antigens and therapeutic molecules. These soft, colloidal, and proteinaceous structures are nevertheless susceptible to environmental factors such as mechanical stress, proteases and low pH which limit their usefulness, particularly for mucosal applications. We addressed this issue by crosslinking multiple surface sites using polyethylene glycol linkers. Surface crosslinking enhanced the colloidal stability and mechanical strength of VLPs against pH, proteases, and mechanical stresses. Chemical crosslinking thus offers a viable means to enhance resilience of VLPs in mucosal applications. Teaser Polyethylene glycol crosslinking virus-like particle (VLP) capsids enhanced the stability and strength of VLPs in mucosal environments.
- Open Access
A rationally designed inactivated Salmonella Typhimurium vaccine induces strong and long-lasting immune responses in pigs
Salmonella enterica subspecies enterica serovar Typhimurium ( S .Tm) poses a considerable threat to public health due to its zoonotic potential. Human infections are mostly foodborne, and pork and pork products are ranked among the top culprits for transmission. In addition, the high percentage of antibiotic resistance, especially in monophasic S .Tm, limits treatment options when needed. Better S .Tm control would therefore be of benefit both for farm animals and for safety of the human food chain. A promising pre-harvest intervention is vaccination. In this study we tested safety and immunogenicity of an oral inactivated S .Tm vaccine, which has been recently shown to generate an “evolutionary trap” and to massively reduce S .Tm colonization and transmission in mice. We show that this vaccine is highly immunogenic and safe in post-weaning pigs and that administration of a single oral dose results in a strong and long-lasting serum IgG response. This has several advantages over existing – mainly live – vaccines against S .Tm, both in improved seroconversion and reduced risk of vaccine-strain persistence and reversion to virulence.
Open AccessA rationally designed inactivated Salmonella Typhimurium vaccine induces strong and long-lasting immune responses in pigs
Salmonella enterica subspecies enterica serovar Typhimurium ( S .Tm) poses a considerable threat to public health due to its zoonotic potential. Human infections are mostly foodborne, and pork and pork products are ranked among the top culprits for transmission. In addition, the high percentage of antibiotic resistance, especially in monophasic S .Tm, limits treatment options when needed. Better S .Tm control would therefore be of benefit both for farm animals and for safety of the human food chain. A promising pre-harvest intervention is vaccination. In this study we tested safety and immunogenicity of an oral inactivated S .Tm vaccine, which has been recently shown to generate an “evolutionary trap” and to massively reduce S .Tm colonization and transmission in mice. We show that this vaccine is highly immunogenic and safe in post-weaning pigs and that administration of a single oral dose results in a strong and long-lasting serum IgG response. This has several advantages over existing – mainly live – vaccines against S .Tm, both in improved seroconversion and reduced risk of vaccine-strain persistence and reversion to virulence.
- Open Access
Vaccine-enhanced competition permits rational bacterial strain replacement in the gut
Widespread antimicrobial resistance generates an urgent need to develop better disease prophylaxis for intestinal bacterial pathogens. While the first phase of infection with any bacterial pathogen is typically colonization of the mucosal surfaces, current vaccine strategies typically target invasive stages of disease. Here we demonstrate the ability to specifically generate sterilizing immunity against Salmonella enterica subspecies enterica serovar Typhimurium (S.Tm) at the level of gut lumen colonization using a combination of oral vaccination and a rationally-designed niche competitor strain. This is based on the proven ability of specific secretory IgA to generate a fitness disadvantage for a targeted bacterium, allowing a non-targeted competitor to rapidly overtake its niche. By hugely decreasing the population size of an intestinal pathogen during the early stages of infection, this improves protection of gut tissue compared to standard licensed animal vaccines. We demonstrate that most effective protection is generated when the niche competitor is derived from the pathogen and therefore occupies an identical niche. However, as this is unrealistic in real-world infections, we further demonstrate that robust protection can also be generated with a more distantly related “probiotic” niche competitor from a distinct species. Interestingly, focusing prophylaxis on the gut lumen reveals an uncoupling of protective mechanisms required for protection in the gut and gut tissues and those required for protecting against colonization of the spleen and liver. Therefore, while there is still potential to improve this approach by adding systemic immune activation, we nevertheless believe this is a fundamental step forward in our ability to manipulate colonization of intestinal bacteria with potential application to a wide-range of entero-pathogens, as well as to manipulation of microbiota composition.
Open AccessVaccine-enhanced competition permits rational bacterial strain replacement in the gut
Widespread antimicrobial resistance generates an urgent need to develop better disease prophylaxis for intestinal bacterial pathogens. While the first phase of infection with any bacterial pathogen is typically colonization of the mucosal surfaces, current vaccine strategies typically target invasive stages of disease. Here we demonstrate the ability to specifically generate sterilizing immunity against Salmonella enterica subspecies enterica serovar Typhimurium (S.Tm) at the level of gut lumen colonization using a combination of oral vaccination and a rationally-designed niche competitor strain. This is based on the proven ability of specific secretory IgA to generate a fitness disadvantage for a targeted bacterium, allowing a non-targeted competitor to rapidly overtake its niche. By hugely decreasing the population size of an intestinal pathogen during the early stages of infection, this improves protection of gut tissue compared to standard licensed animal vaccines. We demonstrate that most effective protection is generated when the niche competitor is derived from the pathogen and therefore occupies an identical niche. However, as this is unrealistic in real-world infections, we further demonstrate that robust protection can also be generated with a more distantly related “probiotic” niche competitor from a distinct species. Interestingly, focusing prophylaxis on the gut lumen reveals an uncoupling of protective mechanisms required for protection in the gut and gut tissues and those required for protecting against colonization of the spleen and liver. Therefore, while there is still potential to improve this approach by adding systemic immune activation, we nevertheless believe this is a fundamental step forward in our ability to manipulate colonization of intestinal bacteria with potential application to a wide-range of entero-pathogens, as well as to manipulation of microbiota composition.
- 27 May 2021
- Published by Springer Nature in Nature Microbiology
- Vol. 6 (7) , 830-841
A rationally designed oral vaccine induces immunoglobulin A in the murine gut that directs the evolution of attenuated Salmonella variants
The ability of gut bacterial pathogens to escape immunity by antigenic variation—particularly via changes to surface-exposed antigens—is a major barrier to immune clearance1. However, not all variants are equally fit in all environments2,3. It should therefore be possible to exploit such immune escape mechanisms to direct an evolutionary trade-off. Here, we demonstrate this phenomenon using Salmonella enterica subspecies enterica serovar Typhimurium (S.Tm). A dominant surface antigen of S.Tm is its O-antigen: a long, repetitive glycan that can be rapidly varied by mutations in biosynthetic pathways or by phase variation4,5. We quantified the selective advantage of O-antigen variants in the presence and absence of O-antigen-specific immunoglobulin A and identified a set of evolutionary trajectories allowing immune escape without an associated fitness cost in naive mice. Through the use of rationally designed oral vaccines, we induced immunoglobulin A responses blocking all of these trajectories. This selected for Salmonella mutants carrying deletions of the O-antigen polymerase gene wzyB. Due to their short O-antigen, these evolved mutants were more susceptible to environmental stressors (detergents or complement) and predation (bacteriophages) and were impaired in gut colonization and virulence in mice. Therefore, a rationally induced cocktail of intestinal antibodies can direct an evolutionary trade-off in S.Tm. This lays the foundations for the exploration of mucosal vaccines capable of setting evolutionary traps as a prophylactic strategy.
- 27 May 2021
- Published by Springer Nature in Nature Microbiology
- Vol. 6 (7) , 830-841
A rationally designed oral vaccine induces immunoglobulin A in the murine gut that directs the evolution of attenuated Salmonella variants
The ability of gut bacterial pathogens to escape immunity by antigenic variation—particularly via changes to surface-exposed antigens—is a major barrier to immune clearance1. However, not all variants are equally fit in all environments2,3. It should therefore be possible to exploit such immune escape mechanisms to direct an evolutionary trade-off. Here, we demonstrate this phenomenon using Salmonella enterica subspecies enterica serovar Typhimurium (S.Tm). A dominant surface antigen of S.Tm is its O-antigen: a long, repetitive glycan that can be rapidly varied by mutations in biosynthetic pathways or by phase variation4,5. We quantified the selective advantage of O-antigen variants in the presence and absence of O-antigen-specific immunoglobulin A and identified a set of evolutionary trajectories allowing immune escape without an associated fitness cost in naive mice. Through the use of rationally designed oral vaccines, we induced immunoglobulin A responses blocking all of these trajectories. This selected for Salmonella mutants carrying deletions of the O-antigen polymerase gene wzyB. Due to their short O-antigen, these evolved mutants were more susceptible to environmental stressors (detergents or complement) and predation (bacteriophages) and were impaired in gut colonization and virulence in mice. Therefore, a rationally induced cocktail of intestinal antibodies can direct an evolutionary trade-off in S.Tm. This lays the foundations for the exploration of mucosal vaccines capable of setting evolutionary traps as a prophylactic strategy.
- Open Access
- 10 March 2021
- Published by Frontiers Media SA in Frontiers for Young Minds
- Vol. 9
How the Gut Microbiota Influences Our Health and How We Can Influence It
The microbes in the human gut, also known as the gut microbiota, are known to play a part in how we feel and whether we are healthy or sick. How the microbiota regulates health is still unknown in most cases, and medical treatments to manipulate the microbiota to improve people’s health are only just starting to be used. In this article, we explain how the gut microbiota is currently studied, what we already understand about how the gut microbiota influences health, and ways that are already used, or are being investigated, to influence the microbiota to improve health.
- 10 March 2021
- Published by Frontiers Media SA in Frontiers for Young Minds
- Vol. 9
Open AccessHow the Gut Microbiota Influences Our Health and How We Can Influence It
The microbes in the human gut, also known as the gut microbiota, are known to play a part in how we feel and whether we are healthy or sick. How the microbiota regulates health is still unknown in most cases, and medical treatments to manipulate the microbiota to improve people’s health are only just starting to be used. In this article, we explain how the gut microbiota is currently studied, what we already understand about how the gut microbiota influences health, and ways that are already used, or are being investigated, to influence the microbiota to improve health.